Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219994 · ClinicalTrials.gov registry record · NA
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
A NA study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT05219994 is a NA study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 22 participants.
The verdict
NCT05219994, a NA study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.
Interventions
- OTHER Hyperoxia Exposure
- OTHER Normoxia Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2023-05-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05219994
The ClinicalTrials.gov registry entry for NCT05219994 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hyperoxia Exposure is the first listed.
NCT05219994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05219994 about?
NCT05219994 is a clinical study titled "Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum". Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.
What is the current status of trial NCT05219994?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2020-09-09. Estimated completion is 2023-05-10.
What interventions are being tested in trial NCT05219994?
The interventions under investigation include: Hyperoxia Exposure (OTHER), Normoxia Exposure (OTHER).
Who is sponsoring clinical trial NCT05219994?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.